Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis

The aim of this review was to study the evidence base for the efficacy and safety of the P2Y12 receptor blocker ticagrelor in combination with acetylsalicylic acid in patients with stable coronary artery disease and high and moderate risk of adverse cardiovascular events. Currently, the mortality ra...

Full description

Bibliographic Details
Main Author: T. N. Novikova
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2020-09-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/4094
_version_ 1797856720117039104
author T. N. Novikova
author_facet T. N. Novikova
author_sort T. N. Novikova
collection DOAJ
description The aim of this review was to study the evidence base for the efficacy and safety of the P2Y12 receptor blocker ticagrelor in combination with acetylsalicylic acid in patients with stable coronary artery disease and high and moderate risk of adverse cardiovascular events. Currently, the mortality rate of this category of patients remains high. Long-term dual antithrombotic therapy allows to improve the prognosis. Ticagrelor at a low dose (60 mg 2 times a day) in combination with acetylsalicylic acid in randomized clinical trials and an actual clinical practice has shown a beneficial effect on prognosis in stable coronary artery disease.
first_indexed 2024-04-09T20:45:07Z
format Article
id doaj.art-f411e44a141a4806a9f49a0007c7f72d
institution Directory Open Access Journal
issn 1560-4071
2618-7620
language Russian
last_indexed 2024-04-09T20:45:07Z
publishDate 2020-09-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj.art-f411e44a141a4806a9f49a0007c7f72d2023-03-29T21:23:36Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202020-09-01253S10.15829/1560-4071-2020-40943051Ticagrelor in patients with stable coronary artery disease: a role in improving prognosisT. N. Novikova0I. I. Mechnikov North-Western State Medical UniversityThe aim of this review was to study the evidence base for the efficacy and safety of the P2Y12 receptor blocker ticagrelor in combination with acetylsalicylic acid in patients with stable coronary artery disease and high and moderate risk of adverse cardiovascular events. Currently, the mortality rate of this category of patients remains high. Long-term dual antithrombotic therapy allows to improve the prognosis. Ticagrelor at a low dose (60 mg 2 times a day) in combination with acetylsalicylic acid in randomized clinical trials and an actual clinical practice has shown a beneficial effect on prognosis in stable coronary artery disease.https://russjcardiol.elpub.ru/jour/article/view/4094stable coronary artery diseasehigh and moderate risk of cardiovascular eventsdual antiplatelet therapyticagrelor
spellingShingle T. N. Novikova
Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis
Российский кардиологический журнал
stable coronary artery disease
high and moderate risk of cardiovascular events
dual antiplatelet therapy
ticagrelor
title Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis
title_full Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis
title_fullStr Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis
title_full_unstemmed Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis
title_short Ticagrelor in patients with stable coronary artery disease: a role in improving prognosis
title_sort ticagrelor in patients with stable coronary artery disease a role in improving prognosis
topic stable coronary artery disease
high and moderate risk of cardiovascular events
dual antiplatelet therapy
ticagrelor
url https://russjcardiol.elpub.ru/jour/article/view/4094
work_keys_str_mv AT tnnovikova ticagrelorinpatientswithstablecoronaryarterydiseasearoleinimprovingprognosis